<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">surgonco</journal-id><journal-title-group><journal-title xml:lang="ru">Креативная хирургия и онкология</journal-title><trans-title-group xml:lang="en"><trans-title>Creative surgery and oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2076-3093</issn><issn pub-type="epub">2307-0501</issn><publisher><publisher-name>Башкирский государственный медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24060/2076-3093-2026-16-2-129-136</article-id><article-id custom-type="elpub" pub-id-type="custom">surgonco-1210</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Циторедуктивные операции в лечении распространенного рака яичников. Опыт и анализ результатов</article-title><trans-title-group xml:lang="en"><trans-title>Cytoreductive Surgery in the Management of Advanced Ovarian Cancer: Experience and Outcome Analysis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-5718-1633</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петров</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrov</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Петров Александр Сергеевич — отделение онкогинекологии</p><p>Курган</p></bio><bio xml:lang="en"><p>Aleksandr S. Petrov — Oncogynecology Unit</p><p>Kurgan</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-6523-9815</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кудравец</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Kudravets</surname><given-names>A. Е.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кудравец Артем Евгеньевич — отделение абдоминальной онкологии</p><p>Курган</p></bio><bio xml:lang="en"><p>Artem Е. Kudravets — Abdominal Oncology Unit</p><p>Kurgan</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1248-8555</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Власов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Vlasov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Власов Артем Александрович — к.м.н.,  отделение телемедицинских технологий, внутреннего контроля качества и безопасности медицинской деятельности</p><p>Курган</p></bio><bio xml:lang="en"><p>Artem А. Vlasov — Cand. Sci. (Med.), Unit of Telemedicine Technologies, Internal Quality Control and Safety of Medical Activities</p><p>Kurgan</p></bio><email xlink:type="simple">dronco2014@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-3862-120X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гурецкая</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Guretskaya</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гурецкая Светлана Александровна — отделение онкогинекологии</p><p>Курган</p></bio><bio xml:lang="en"><p>Svetlana А. Guretskaya — Oncogynecology Unit</p><p>Kurgan</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-4440-2995</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Помигуева</surname><given-names>К. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Pomigueva</surname><given-names>K. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Помигуева Кристина Сергеевна — отделение онкогинекологии</p><p>Курган</p></bio><bio xml:lang="en"><p>Kristina S. Pomigueva — Oncogynecology Unit</p><p>Kurgan</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-1812-7202</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шанаурова</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shanaurova</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шанаурова Вероника Александровна — отделение онкогинекологии</p><p>Курган</p></bio><bio xml:lang="en"><p>Veronika А. Shanaurova — Oncogynecology Unit</p><p>Kurgan</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Курганский областной онкологический диспансер</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kurgan Regional Oncology Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>03</day><month>07</month><year>2026</year></pub-date><volume>16</volume><issue>2</issue><fpage>129</fpage><lpage>136</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Петров А.С., Кудравец А.Е., Власов А.А., Гурецкая С.А., Помигуева К.С., Шанаурова В.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Петров А.С., Кудравец А.Е., Власов А.А., Гурецкая С.А., Помигуева К.С., Шанаурова В.А.</copyright-holder><copyright-holder xml:lang="en">Petrov A.S., Kudravets A.Е., Vlasov A.A., Guretskaya S.A., Pomigueva K.S., Shanaurova V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surgonco.ru/jour/article/view/1210">https://www.surgonco.ru/jour/article/view/1210</self-uri><abstract><sec><title>Введение</title><p>Введение. Рак яичников считается одной из основных причин смерти у женщин. По оценкам, заболеваемость во всем мире составляет приблизительно 200 000 новых случаев в год, а смертность составляет 100 000 человек. Большинство опухолей яичников диагностируется на поздней стадии и только 25–30 % — на ранней стадии. При распространенном раке яичников целью хирургического лечения является достижение полной циторедукции всех макроскопически видимых новообразований, поскольку именно это способствует увеличению общей выживаемости и безрецидивного периода заболевания. Цель: определить влияние полной циторедуктивной операции на ранние послеоперационные осложнения и  летальность, а  также общую выживаемость при распространенном раке яичников в отдаленном периоде.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Мы ретроспективно проанализировали медицинские данные пациенток, перенесших первичную циторедуктивную операцию по  поводу распространенного рака яичников в  Курганском областном онкологическом диспансере в период с 1 января 2017 года по 1 января 2025 года.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. В общей сложности 54 женщинам была проведена циторедуктивная операция; у 90,7 % (n = 49) она была полной, а у 9,3 % (n = 5) — неполной. Количество соседних резецированных органов за операцию составило от 1 (53,6 %) до 5 (5,6 %), в среднем 2,02 ± 1,28. У пациенток, перенесших циторедукцию, частота послеоперационных осложнений составила 51,9 % (n = 28), 4-й степени — 5,6 % (n = 3) и 5-й степени — 1,9 % (n = 1) по шкале Clavien—Dindo. Также была определена длительность операций, которая составила в среднем 365,61 ± 176,08 минуты, при диапазоне 90–820 минут. Однако у пациенток, которым была выполнена полная циторедукция, не было отмечено увеличения числа серьезных послеоперационных осложнений и летальности (4–5-й степени по шкале Clavien—Dindo).</p></sec><sec><title>Заключение</title><p>Заключение. Более обширный хирургический подход полностью оправдан и связан с улучшением выживаемости у пациенток с раком яичников на поздней стадии. Однако отбор пациенток должен проводиться тщательно, поскольку общее предоперационное состояние может существенно повлиять на выживаемость.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Ovarian cancer remains one of the leading causes of cancer‑related mortality among women. Globally, approximately 200,000 new cases and 100,000 deaths are reported annually. Most ovarian tumors are diagnosed at an advanced stage, while only 25–30 % are detected early. In advanced disease, the primary objective of surgical treatment is complete cytoreduction of all macroscopically visible disease, as this factor is strongly associated with improved overall survival and longer progression‑free intervals. Aim. This study evaluated the effect of complete cytoreductive surgery on early postoperative complications, mortality, and long‑term overall survival in patients with advanced ovarian cancer.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. We conducted a retrospective review of medical records for patients who underwent primary cytoreductive surgery for advanced ovarian cancer at the Kurgan Regional Oncology Center between 1 January 2017 and 1 January 2025.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. A total of 54 women underwent cytoreductive surgery. Complete cytoreduction was achieved in 90.7% (n = 49), while 9.3 % (n = 5) had residual disease. The number of adjacent organs resected ranged from 1 (53.6 %) to 5 (5.6 %), with a mean of 2.02 ± 1.28. Postoperative complications occurred in 51.9% (n = 28) of patients; grade IV complications occurred in 5.6 % (n = 3) and grade V in 1.9% (n = 1) according to the Clavien–Dindo classification. Mean operative time was 365.61 ± 176.08 minutes (range of 90–820 minutes). Importantly, patients who underwent complete cytoreduction did not exhibit higher rates of severe postoperative complications or mortality (Clavien–Dindo grades IV–V).</p></sec><sec><title>Conclusion</title><p>Conclusion. A more extensive surgical approach is justified in selected patients with advanced ovarian cancer and is associated with improved survival. However, careful patient selection is essential, as overall preoperative status may significantly influence survival outcomes.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>распространенный рак яичников</kwd><kwd>циторедуктивные операции</kwd><kwd>послеоперационные осложнения</kwd><kwd>выживаемость</kwd><kwd>летальность</kwd><kwd>хирургическая циторедукция</kwd><kwd>гистерэктомия</kwd><kwd>адъювантная химиотерапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>advanced ovarian cancer</kwd><kwd>cytoreductive surgery</kwd><kwd>postoperative complications</kwd><kwd>survival</kwd><kwd>mortality</kwd><kwd>surgical cytoreduction</kwd><kwd>hysterectomy</kwd><kwd>adjuvant chemotherapy</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Данная работа не финансировалась.</funding-statement><funding-statement xml:lang="en">This work is not funded.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2024 году. Москва: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2025.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D, Starinsky V.V., Shakhzadova A.O. State of cancer care for population in Russia in 2024. − Moscow: P.A. Herzen Moscow Research Oncolofy Institute — branch of the National Medical Research Center for Radiology, Ministry of Health of the Russian Federation, 2025 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Мерабишвили В.М., Бахидзе Е.В., Урманчеева А.Ф., Городнова Т.В., Ульрих Е.А., Беляева А.В. и др. Состояние онкологической помощи в России: рак яичников, распространенность, качество учета, выживаемость больных (клинико-популяционное исследование. Вопросы онкологии. 2025;71(2):306–17. DOI: 10.37469/0507-3758-2025-71-2-306-317</mixed-citation><mixed-citation xml:lang="en">Merabishvili V.M., Bakhidze E.V., Urmancheeva A.F., Gorodnova T.V., Ulrich E.A., Belyaeva A.V., et al. Cancer care in Russia: ovarian cancer, prevalence, registration quality, survival (clinical and population study). Voprosy Onkologii. 2025;71(2):306–17 (In Russ.). DOI: 10.37469/0507-3758-2025-71-2-306-317</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lin Q., Liu W., Guo Y., Wang X. Secondary cytoreductive surgery in platinum-sensitive relapsed ovarian cancer: a meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2025;311(2):405–14. DOI: 10.1007/s00404-024-07863-x</mixed-citation><mixed-citation xml:lang="en">Lin Q., Liu W., Guo Y., Wang X. Secondary cytoreductive surgery in platinum-sensitive relapsed ovarian cancer: a meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2025;311(2):405–14. DOI: 10.1007/s00404-024-07863-x</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vitale S.G., Marilli I., Lodato M., Tropea A., Cianci A.The role of cytoreductive surgery in advanced-stage ovarian cancer: a systematic review. Updates Surg. 2013;65:265–70. DOI: 10.1007/s13304-013-0213-4</mixed-citation><mixed-citation xml:lang="en">Vitale S.G., Marilli I., Lodato M., Tropea A., Cianci A.The role of cytoreductive surgery in advanced-stage ovarian cancer: a systematic review. Updates Surg. 2013;65:265–70. DOI: 10.1007/s13304-013-0213-4</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fumagalli D., Jayraj A., Olearo E., Capasso I., Hsu H.C., Tzur Y., et al. Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer. Int J Gynecol Cancer. 2025;35(3):101664. DOI: 10.1016/j.ijgc.2025.101664</mixed-citation><mixed-citation xml:lang="en">Fumagalli D., Jayraj A., Olearo E., Capasso I., Hsu H.C., Tzur Y., et al. Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer. Int J Gynecol Cancer. 2025;35(3):101664. DOI: 10.1016/j.ijgc.2025.101664</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Туромша А.Н., Протасова А.Э., Раскин Г.А., Кравцова Е.Д., Андреев А.Л., Страх Л.В. и др. Рак яичников in situ: клинический случай. Опухоли женской репродуктивной системы. 2024;20(3):95–8. DOI: 10.17650/1994-4098-2024-20-3-95-98</mixed-citation><mixed-citation xml:lang="en">Turomsha A.N., Protasova A.E., Raskin G.A., Kravtsova E.D., Andreev A.L., Strakh L.V., et al. Ovarian cancer in situ: a case report. Tumors of female reproductive system. 2024;20(3):95–8 (In Russ.). DOI: 10.17650/1994-4098-2024-20-3-95-98</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнова А.В., Малышкина А.И., Хрушкова Е.П. Особенности ранней диагностики новообразований яичников. РМЖ. Мать и дитя. 2023;6(2):105–11. DOI: 10.32364/2618-8430-2023-6-2-105-111</mixed-citation><mixed-citation xml:lang="en">Smirnova A.V., Malyshkina A.I., Khrushkova E.P. Characteristics in early diagnosis of ovarian masses. Russian Journal of Woman and Child Health. 2023;6(2):105–11 (In Russ.). DOI: 10.32364/2618-8430-2023-6-2-105-111</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lheureux S., Braunstein M., Oza A.M. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304. DOI: 10.3322/caac.21559</mixed-citation><mixed-citation xml:lang="en">Lheureux S., Braunstein M., Oza A.M. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304. DOI: 10.3322/caac.21559</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Arab M., Jamdar F., Sadat Hosseini M., Ghodssi- Ghasemabadi R., Farzaneh F., Ashrafganjoei T. Model for prediction of optimal debulking of epithelial ovarian cancer. Asian Pac J Cancer Prev. 2018;19(5):1319–24. DOI: 10.22034/APJCP.2018.19.5.1319</mixed-citation><mixed-citation xml:lang="en">Arab M., Jamdar F., Sadat Hosseini M., Ghodssi- Ghasemabadi R., Farzaneh F., Ashrafganjoei T. Model for prediction of optimal debulking of epithelial ovarian cancer. Asian Pac J Cancer Prev. 2018;19(5):1319–24. DOI: 10.22034/APJCP.2018.19.5.1319</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Onda T., Satoh T., Ogawa G., Saito T., Kasamatsu T., Nakanishi T., et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer. 2020;130:114–25. DOI: 10.1016/j.ejca.2020.02.020</mixed-citation><mixed-citation xml:lang="en">Onda T., Satoh T., Ogawa G., Saito T., Kasamatsu T., Nakanishi T., et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer. 2020;130:114–25. DOI: 10.1016/j.ejca.2020.02.020</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Narasimhulu D.M., Bews K.A., Hanson K.T., Chang Y.H., Dowdy S.C., Cliby W.A. Using evidence to direct quality improvement efforts: Defining the highest impact complications after complex cytoreductive surgery for ovarian cancer. Gynecol Oncol. 2020;156(2):278–83. DOI: 10.1016/j.ygyno.2019.11.007</mixed-citation><mixed-citation xml:lang="en">Narasimhulu D.M., Bews K.A., Hanson K.T., Chang Y.H., Dowdy S.C., Cliby W.A. Using evidence to direct quality improvement efforts: Defining the highest impact complications after complex cytoreductive surgery for ovarian cancer. Gynecol Oncol. 2020;156(2):278–83. DOI: 10.1016/j.ygyno.2019.11.007</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wimberger P., Lehmann N., Kimmig R., Burges A., Meier W., Du Bois A., et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2007;106(1):69–74. DOI: 10.1016/j.ygyno.2007.02.026</mixed-citation><mixed-citation xml:lang="en">Wimberger P., Lehmann N., Kimmig R., Burges A., Meier W., Du Bois A., et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2007;106(1):69–74. DOI: 10.1016/j.ygyno.2007.02.026</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Morrison J., Swanton A., Collins S., Kehoe S. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database System Rev. 2007;(4):CD005343. DOI: 10.1002/14651858.CD005343.pub2</mixed-citation><mixed-citation xml:lang="en">Morrison J., Swanton A., Collins S., Kehoe S. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database System Rev. 2007;(4):CD005343. DOI: 10.1002/14651858.CD005343.pub2</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ye S., He T., Liang S., Chen X., Wu X., Yang H., et al. Diaphragmatic surgery and related complications in primary cytoreduction for advanced ovarian, tubal, and peritoneal carcinoma. BMC Cancer. 2017;17(1):317. DOI: 10.1186/s12885-017-3311-8</mixed-citation><mixed-citation xml:lang="en">Ye S., He T., Liang S., Chen X., Wu X., Yang H., et al. Diaphragmatic surgery and related complications in primary cytoreduction for advanced ovarian, tubal, and peritoneal carcinoma. BMC Cancer. 2017;17(1):317. DOI: 10.1186/s12885-017-3311-8</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bartels H.C., Rogers A.C., McSharry V., McVey R., Walsh T., O’Brien D., et al. A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy. Gynecol Oncol. 2019;154(3):622– 30. DOI: 10.1016/j.ygyno.2019.07.011</mixed-citation><mixed-citation xml:lang="en">Bartels H.C., Rogers A.C., McSharry V., McVey R., Walsh T., O’Brien D., et al. A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy. Gynecol Oncol. 2019;154(3):622– 30. DOI: 10.1016/j.ygyno.2019.07.011</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cliby W.A., Powell M.A., Al-Hammadi N., Chen L., Philip Miller J., Roland P.Y., et al. Ovarian cancer in the United States: contemporary patterns of care associated with improved survival. Gynecol Oncol. 2015;136(1):11–7. DOI: 10.1016/j.ygyno.2014.10.023</mixed-citation><mixed-citation xml:lang="en">Cliby W.A., Powell M.A., Al-Hammadi N., Chen L., Philip Miller J., Roland P.Y., et al. Ovarian cancer in the United States: contemporary patterns of care associated with improved survival. Gynecol Oncol. 2015;136(1):11–7. DOI: 10.1016/j.ygyno.2014.10.023</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Jeon S., Lee S.J., Lim M.C., Song T., Bae J., Kim K., et al. Surgical manual of the Korean Gynecologic Oncology Group: ovarian, tubal, and peritoneal cancers. J Gynecol Oncol. 2017;28(1):e6. DOI: 10.3802/jgo.2017.28.e6</mixed-citation><mixed-citation xml:lang="en">Jeon S., Lee S.J., Lim M.C., Song T., Bae J., Kim K., et al. Surgical manual of the Korean Gynecologic Oncology Group: ovarian, tubal, and peritoneal cancers. J Gynecol Oncol. 2017;28(1):e6. DOI: 10.3802/jgo.2017.28.e6</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sinno A.K., Li X., Thompson R.E., Tanner E.J. 3rd, Levinson K.L., Stone R.L., et al. Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care. Gynecol Oncol. 2017;145(3):493–9. DOI: 10.1016/j.ygyno.2017.03.020</mixed-citation><mixed-citation xml:lang="en">Sinno A.K., Li X., Thompson R.E., Tanner E.J. 3rd, Levinson K.L., Stone R.L., et al. Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care. Gynecol Oncol. 2017;145(3):493–9. DOI: 10.1016/j.ygyno.2017.03.020</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Mueller J.J., Lajer H., Mosgaard B.J., Bach Hamba S., Morice P., Gouy S., et al. International study of primary mucinous ovarian carcinomas managed at tertiary medical centers. Int J Gynecol Cancer. 2018;28(5):915–24. DOI: 10.1097/IGC.0000000000001263</mixed-citation><mixed-citation xml:lang="en">Mueller J.J., Lajer H., Mosgaard B.J., Bach Hamba S., Morice P., Gouy S., et al. International study of primary mucinous ovarian carcinomas managed at tertiary medical centers. Int J Gynecol Cancer. 2018;28(5):915–24. DOI: 10.1097/IGC.0000000000001263</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">ClinicalTrials.Gov. Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST). Available from: https://clinicaltrials.gov/study/NCT02828618 [cited 2025 Aug 7].</mixed-citation><mixed-citation xml:lang="en">ClinicalTrials. Gov. Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST). Available from: https://clinicaltrials.gov/study/NCT02828618 [cited 2025 Aug 7].</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Shi T., Chen Y., Jiang R., Xiang L., Liu J., Zhu J., et al. Optimal timing of primary debulking surgery in advanced ovarian cancer: insights from the TRUST trial. J Gynecol Oncol. 2025;36(5):e132. DOI: 10.3802/jgo.2025.36.e132</mixed-citation><mixed-citation xml:lang="en">Shi T., Chen Y., Jiang R., Xiang L., Liu J., Zhu J., et al. Optimal timing of primary debulking surgery in advanced ovarian cancer: insights from the TRUST trial. J Gynecol Oncol. 2025;36(5):e132. DOI: 10.3802/jgo.2025.36.e132</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Dahm-Kähler P., Rådestad A.F., Holmberg E., Borgfeldt C., Bjurberg M., Sköld C., et al. Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? — A population-based nationwide SweGCG study. Gynecol Oncol. 2024;186:69–76. DOI: 10.1016/j.ygyno.2024.03.011</mixed-citation><mixed-citation xml:lang="en">Dahm-Kähler P., Rådestad A.F., Holmberg E., Borgfeldt C., Bjurberg M., Sköld C., et al. Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? — A population-based nationwide SweGCG study. Gynecol Oncol. 2024;186:69–76. DOI: 10.1016/j.ygyno.2024.03.011</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Василькин Д.И., Дамбаев Г.Ц., Соловьёв М.М., Фатюшина О.А., Власов А.А. Компрессионные анастомозы при операциях на толстой кишке (обзор литературы). Вопросы реконструктивной и пластической хирургии. 2023;26(1(84)):15–29. DOI: 10.52581/1814-1471/84/02</mixed-citation><mixed-citation xml:lang="en">Vasilkin D.I., Dambaev G.Ts., Soloviev M.M., Fatyushina O.A., Vlasov A.A. Compression anastomoses in colon surgery (literature review). Issues of Reconstructive and Plastic Surgery. 2023;26(1):15–29 (In Russ.). DOI: 10.52581/1814-1471/84/02</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
